E-cadherins are epithelial morphological stabilizers, performing complex functions as receptors, providers of cellular and tissular structural integrity, and functional interactive mediators. Structural and functional unbalance initiated due to E-cadherin expression loss results in direct effects on carcinogenesis specific biological processes, as cellular invasion and proliferation. We investigated the E-cadherin expression aiming (i) to identify the differences in the molecular subtypes of breast cancer, (ii) to analyze the correlations between E-cadherin and specific clinicopathological and molecular characteristics. The study included 42 cases that were investigated immunohistochemically using a panel of antibodies (ER, PR, Her2/neu, CK5/6, EGFR), which permitted a diagnostic in compliance with the molecular classification, followed by the E-cadherin evaluation. The semi-quantitative assessment of E-cadherin was performed using a scoring system based on the positive cells percentage and the staining intensity. Our results showed, according to the molecular subtypes, a strong positive E-cadherin expression in 26 cases (luminal A subtype - nine cases, luminal B subtype - five cases, HER2 subtype - three cases, basal-like subtype - seven cases, unclassified subtype - two cases), and a weak positive one in 16 cases (luminal A subtype - six cases, luminal B subtype - eight cases, HER2 subtype - one case, basal-like subtype - one case). The statistical analysis revealed significantly statistical differences between E-cadherin and tumoral grade (p=0.0208), histological subtype (p=0.0081), triple negative molecular subtypes and non-triple negative, respectively (p=0.0361). These findings support the potential value of E-cadherin for a supplementary differentiation of molecular subtypes, based on the biological significance of its capacity of expression.

Download full-text PDF

Source

Publication Analysis

Top Keywords

subtype cases
24
e-cadherin expression
16
molecular subtypes
16
cases luminal
16
luminal subtype
16
cases
10
subtype
10
e-cadherin
9
cases her2
8
her2 subtype
8

Similar Publications

In women globally, breast cancer ranks as the second most frequent cause of cancer-related deaths, making up about 25% of female cancer cases, which is pretty standard in affluent countries. Breast cancer is divided into subtypes based on aggressive, genetic and stage. The precise cause of the problem is still unknown.

View Article and Find Full Text PDF

Lung cancer is correlated with a high death rate, with approximately 1.8 million mortality cases reported worldwide in 2022. Despite development in the control of lung cancer, most cases are detected at higher stages with short survival rates.

View Article and Find Full Text PDF

Advances in imaging techniques have evolved, allowing for early noninvasive diagnosis and improved management of high-risk patients with hepatocellular carcinoma (HCC). The hallmark imaging features of HCC on multiphasic cross-sectional imaging can be explained by the multistep process of hepatocarcinogenesis and is seen in 60% of cases. However, approximately 40% of cases do not abide by the classic imaging appearance and may pose a diagnostic challenge for radiologists.

View Article and Find Full Text PDF

Analysis of the Clinical Characteristics and Ultrasonographic Features in 141 Cases of Cystic Neutrophilic Granulomatous Mastitis.

Acad Radiol

January 2025

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, PR China (M.W., Y.L., D.Z., N.F., Y.W., M.L., H.Z.).

Rationale And Objectives: To summarize the clinical features and ultrasonic characteristics of patients with cystic neutrophilic granulomatous mastitis (CNGM), and to enhance the understanding of CNGM in clinical practice.

Materials And Methods: This study retrospectively analyzed the demographic data, clinical symptoms, and ultrasonic characteristics of 141 patients diagnosed with CNGM through pathological examination. This study was approved by the Medical Ethical Committee of Beijing Hospital of Traditional Chinese Medicine (2023BL02-054-01).

View Article and Find Full Text PDF

Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer.

J Natl Compr Canc Netw

January 2025

1Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.

Colorectal cancer (CRC) is a heterogeneous group of diseases comprising several molecular subtypes. Comprehensive DNA sequencing is now standard practice to identify these subtype. Until recently, KRAS mutation status in metastatic CRC was primarily used as a biomarker to predict resistance to EGFR inhibition.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!